This selective, oral, potent, non-ATP competitive allosteric site MEK inhibitor was developed by Millenium Pharmaceuticals, Inc. It demonstrated anti-tumor effects in vitro in melanoma cell lines and in vivo in patients-derived xenograft models [202]. This evidence concerns the gene MAP2K7 and melanoma.